nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Respiratory distress—Metformin—polycystic ovary syndrome	0.0308	0.0711	CcSEcCtD
Regadenoson—Clofarabine—RRM2—polycystic ovary syndrome	0.0271	0.635	CrCbGaD
Regadenoson—Chest discomfort—Metformin—polycystic ovary syndrome	0.0221	0.0511	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—SFTPC—polycystic ovary syndrome	0.0167	0.0319	CbGpPWpGaD
Regadenoson—Cladribine—RRM2—polycystic ovary syndrome	0.0155	0.365	CrCbGaD
Regadenoson—Renal impairment—Metformin—polycystic ovary syndrome	0.0149	0.0345	CcSEcCtD
Regadenoson—ADORA2A—Monoamine Transport—TH—polycystic ovary syndrome	0.0145	0.0277	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Other—ADRA1D—polycystic ovary syndrome	0.0145	0.0276	CbGpPWpGaD
Regadenoson—Pain in extremity—Metformin—polycystic ovary syndrome	0.0142	0.0328	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—LHCGR—polycystic ovary syndrome	0.0125	0.0237	CbGpPWpGaD
Regadenoson—Abdominal distension—Metformin—polycystic ovary syndrome	0.0124	0.0285	CcSEcCtD
Regadenoson—Angina pectoris—Metformin—polycystic ovary syndrome	0.012	0.0276	CcSEcCtD
Regadenoson—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.0118	0.0272	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Other—FSHR—polycystic ovary syndrome	0.0117	0.0223	CbGpPWpGaD
Regadenoson—Bradycardia—Metformin—polycystic ovary syndrome	0.01	0.0231	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—PDE3B—polycystic ovary syndrome	0.01	0.0191	CbGpPWpGaD
Regadenoson—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00978	0.0226	CcSEcCtD
Regadenoson—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00966	0.0223	CcSEcCtD
Regadenoson—Eye disorder—Metformin—polycystic ovary syndrome	0.00918	0.0212	CcSEcCtD
Regadenoson—Flushing—Metformin—polycystic ovary syndrome	0.00912	0.0211	CcSEcCtD
Regadenoson—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00912	0.0211	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—FSHR—polycystic ovary syndrome	0.00911	0.0174	CbGpPWpGaD
Regadenoson—Angiopathy—Metformin—polycystic ovary syndrome	0.00892	0.0206	CcSEcCtD
Regadenoson—Immune system disorder—Metformin—polycystic ovary syndrome	0.00888	0.0205	CcSEcCtD
Regadenoson—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00886	0.0205	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—CLDN4—polycystic ovary syndrome	0.00879	0.0168	CbGpPWpGaD
Regadenoson—Erythema—Metformin—polycystic ovary syndrome	0.00856	0.0198	CcSEcCtD
Regadenoson—Dysgeusia—Metformin—polycystic ovary syndrome	0.00838	0.0193	CcSEcCtD
Regadenoson—Vision blurred—Metformin—polycystic ovary syndrome	0.00806	0.0186	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—ADRB3—polycystic ovary syndrome	0.00802	0.0153	CbGpPWpGaD
Regadenoson—Tremor—Metformin—polycystic ovary syndrome	0.00802	0.0185	CcSEcCtD
Regadenoson—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00794	0.0183	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—LHB—polycystic ovary syndrome	0.00793	0.0151	CbGpPWpGaD
Regadenoson—Malaise—Metformin—polycystic ovary syndrome	0.00772	0.0178	CcSEcCtD
Regadenoson—Syncope—Metformin—polycystic ovary syndrome	0.00767	0.0177	CcSEcCtD
Regadenoson—Palpitations—Metformin—polycystic ovary syndrome	0.00756	0.0175	CcSEcCtD
Regadenoson—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00752	0.0174	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—SCT—polycystic ovary syndrome	0.00743	0.0142	CbGpPWpGaD
Regadenoson—Hypertension—Metformin—polycystic ovary syndrome	0.00739	0.0171	CcSEcCtD
Regadenoson—Chest pain—Metformin—polycystic ovary syndrome	0.00728	0.0168	CcSEcCtD
Regadenoson—Myalgia—Metformin—polycystic ovary syndrome	0.00728	0.0168	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00723	0.0167	CcSEcCtD
Regadenoson—Discomfort—Metformin—polycystic ovary syndrome	0.0072	0.0166	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—NPB—polycystic ovary syndrome	0.00711	0.0136	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—SERPINE1—polycystic ovary syndrome	0.00696	0.0133	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—STAR—polycystic ovary syndrome	0.00695	0.0132	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—PTGER3—polycystic ovary syndrome	0.00693	0.0132	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—LHCGR—polycystic ovary syndrome	0.00693	0.0132	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PLEKHG5—polycystic ovary syndrome	0.00691	0.0132	CbGpPWpGaD
Regadenoson—Shock—Metformin—polycystic ovary syndrome	0.00687	0.0159	CcSEcCtD
Regadenoson—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00685	0.0158	CcSEcCtD
Regadenoson—Skin disorder—Metformin—polycystic ovary syndrome	0.00678	0.0157	CcSEcCtD
Regadenoson—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00675	0.0156	CcSEcCtD
Regadenoson—Hypotension—Metformin—polycystic ovary syndrome	0.00652	0.0151	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—PTAFR—polycystic ovary syndrome	0.00648	0.0124	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00636	0.0147	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRA1D—polycystic ovary syndrome	0.00629	0.012	CbGpPWpGaD
Regadenoson—Paraesthesia—Metformin—polycystic ovary syndrome	0.00627	0.0145	CcSEcCtD
Regadenoson—Dyspnoea—Metformin—polycystic ovary syndrome	0.00623	0.0144	CcSEcCtD
Regadenoson—Somnolence—Metformin—polycystic ovary syndrome	0.00621	0.0143	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRA1B—polycystic ovary syndrome	0.00612	0.0117	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00603	0.0139	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—PTGER3—polycystic ovary syndrome	0.00594	0.0113	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—LHCGR—polycystic ovary syndrome	0.00594	0.0113	CbGpPWpGaD
Regadenoson—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00575	0.0133	CcSEcCtD
Regadenoson—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00571	0.0132	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—PTAFR—polycystic ovary syndrome	0.00555	0.0106	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Other—ADRB2—polycystic ovary syndrome	0.00555	0.0106	CbGpPWpGaD
Regadenoson—Urticaria—Metformin—polycystic ovary syndrome	0.00555	0.0128	CcSEcCtD
Regadenoson—Abdominal pain—Metformin—polycystic ovary syndrome	0.00552	0.0127	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—NPB—polycystic ovary syndrome	0.00542	0.0103	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.00539	0.0103	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRA1B—polycystic ovary syndrome	0.00524	0.01	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—FSHR—polycystic ovary syndrome	0.00507	0.00967	CbGpPWpGaD
Regadenoson—Asthenia—Metformin—polycystic ovary syndrome	0.00501	0.0116	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—MTNR1B—polycystic ovary syndrome	0.00482	0.00918	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—polycystic ovary syndrome	0.00478	0.00913	CbGpPWpGaD
Regadenoson—Diarrhoea—Metformin—polycystic ovary syndrome	0.00478	0.011	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGF18—polycystic ovary syndrome	0.00464	0.00885	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRA1A—polycystic ovary syndrome	0.00464	0.00885	CbGpPWpGaD
Regadenoson—Dizziness—Metformin—polycystic ovary syndrome	0.00462	0.0107	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.00452	0.00862	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.00452	0.00862	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB3—polycystic ovary syndrome	0.00446	0.00851	CbGpPWpGaD
Regadenoson—Vomiting—Metformin—polycystic ovary syndrome	0.00444	0.0103	CcSEcCtD
Regadenoson—Rash—Metformin—polycystic ovary syndrome	0.0044	0.0102	CcSEcCtD
Regadenoson—Dermatitis—Metformin—polycystic ovary syndrome	0.0044	0.0102	CcSEcCtD
Regadenoson—Headache—Metformin—polycystic ovary syndrome	0.00437	0.0101	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00434	0.00829	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—ADRB2—polycystic ovary syndrome	0.00433	0.00826	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—GAB1—polycystic ovary syndrome	0.00424	0.00808	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00423	0.00806	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NAMPT—polycystic ovary syndrome	0.00421	0.00803	CbGpPWpGaD
Regadenoson—Nausea—Metformin—polycystic ovary syndrome	0.00415	0.00958	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.0041	0.00783	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—GNAS—polycystic ovary syndrome	0.00402	0.00766	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00399	0.00762	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00397	0.00758	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.00394	0.00752	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TOP2A—polycystic ovary syndrome	0.00383	0.0073	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00382	0.0073	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—TNRC6B—polycystic ovary syndrome	0.00379	0.00723	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00378	0.00721	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00369	0.00705	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGF18—polycystic ovary syndrome	0.00357	0.00681	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—GHRL—polycystic ovary syndrome	0.00356	0.00678	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—ADIPOQ—polycystic ovary syndrome	0.00344	0.00657	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.00338	0.00644	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TH—polycystic ovary syndrome	0.00334	0.00638	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ATF1—polycystic ovary syndrome	0.00333	0.00634	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.00331	0.00631	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—GAB1—polycystic ovary syndrome	0.00326	0.00622	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NGFR—polycystic ovary syndrome	0.00313	0.00597	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00306	0.00584	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00303	0.00577	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—TNRC6B—polycystic ovary syndrome	0.00291	0.00556	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00291	0.00556	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00288	0.00549	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00281	0.00537	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00278	0.0053	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00277	0.00528	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00271	0.00517	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00271	0.00517	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—POMC—polycystic ovary syndrome	0.0027	0.00516	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—SCT—polycystic ovary syndrome	0.0027	0.00514	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NCOR1—polycystic ovary syndrome	0.0026	0.00496	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00257	0.00491	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ATF1—polycystic ovary syndrome	0.00256	0.00488	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00255	0.00487	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00255	0.00487	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00251	0.00479	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRG1—polycystic ovary syndrome	0.0025	0.00477	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.0025	0.00476	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00241	0.0046	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00239	0.00456	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NGFR—polycystic ovary syndrome	0.00236	0.0045	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00232	0.00442	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00232	0.00442	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00232	0.00442	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00226	0.0043	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00217	0.00414	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS2—polycystic ovary syndrome	0.00214	0.00409	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—LEP—polycystic ovary syndrome	0.00214	0.00408	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00211	0.00402	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00207	0.00394	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00205	0.00392	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00205	0.00391	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NRG1—polycystic ovary syndrome	0.00192	0.00367	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.0019	0.00362	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00188	0.00358	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS1—polycystic ovary syndrome	0.00187	0.00357	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00187	0.00357	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00186	0.00356	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARG—polycystic ovary syndrome	0.00186	0.00355	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT2—polycystic ovary syndrome	0.00173	0.0033	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00171	0.00326	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.0017	0.00324	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—SERPINE1—polycystic ovary syndrome	0.00168	0.0032	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IRS2—polycystic ovary syndrome	0.00165	0.00314	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00165	0.00314	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NPB—polycystic ovary syndrome	0.00164	0.00313	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00163	0.0031	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00159	0.00303	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00157	0.003	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00155	0.00296	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00152	0.00291	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00149	0.00285	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00148	0.00283	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00148	0.00282	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.00146	0.00278	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.00145	0.00277	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00144	0.00275	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IRS1—polycystic ovary syndrome	0.00144	0.00275	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00138	0.00264	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00137	0.00261	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00137	0.00261	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT2—polycystic ovary syndrome	0.00133	0.00254	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00132	0.00252	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.00129	0.00246	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00128	0.00244	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00124	0.00237	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00121	0.00231	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00118	0.00225	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.0011	0.0021	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.00107	0.00205	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FSHR—polycystic ovary syndrome	0.001	0.00191	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000982	0.00187	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000975	0.00186	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000943	0.0018	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000917	0.00175	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FST—polycystic ovary syndrome	0.000894	0.0017	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000889	0.0017	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000883	0.00168	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LHB—polycystic ovary syndrome	0.000873	0.00166	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000853	0.00163	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000826	0.00158	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000824	0.00157	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SCT—polycystic ovary syndrome	0.000818	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000807	0.00154	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—polycystic ovary syndrome	0.000799	0.00152	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—polycystic ovary syndrome	0.000783	0.00149	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.00078	0.00149	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000767	0.00146	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RBP4—polycystic ovary syndrome	0.00076	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000748	0.00143	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—YAP1—polycystic ovary syndrome	0.00071	0.00135	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GAB1—polycystic ovary syndrome	0.0007	0.00133	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—INSR—polycystic ovary syndrome	0.000669	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000636	0.00121	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000626	0.00119	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PGR—polycystic ovary syndrome	0.00062	0.00118	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6—polycystic ovary syndrome	0.000602	0.00115	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000576	0.0011	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000576	0.0011	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000555	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	0.00055	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000536	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000533	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000507	0.000967	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000504	0.000961	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRL—polycystic ovary syndrome	0.000503	0.000959	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000484	0.000924	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000477	0.000909	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000442	0.000843	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000421	0.000803	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000413	0.000789	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000354	0.000675	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LEP—polycystic ovary syndrome	0.000347	0.000661	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000309	0.00059	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—POMC—polycystic ovary syndrome	0.000298	0.000568	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—INS—polycystic ovary syndrome	0.000296	0.000565	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000286	0.000546	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000286	0.000546	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000272	0.000519	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000219	0.000418	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000187	0.000357	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—polycystic ovary syndrome	0.000129	0.000247	CbGpPWpGaD
